Non-clinical studies are necessary at each stage of the development of oncology drugs. Many experimental cancer models have been developed to investigate carcinogenesis, cancer progression, metastasis, and other aspects in cancer biology and these models turned out to be useful in the efficacy evaluation and the safety prediction of oncology drugs. While the diversity and the degree of engagement in genetic changes in the initiation of cancer cell growth and progression are widely accepted, it has become increasingly clear that the roles of host cells, tissue microenvironment, and the immune system also play important roles in cancer. Therefore, the methods used to develop oncology drugs should continuously be revised based on the advances in our understanding of cancer. In this review, we extensively summarize the effective use of those models, their advantages and disadvantages, ranges to be evaluated and limitations of the models currently used for the development and for the evaluation of oncology drugs.
Non-clinical studies are necessary at each stage of the development of oncology drugs. Many experimental cancer models have been developed to investigate carcinogenesis, cancer progression, metastasis, and other aspects in cancer biology and these models turned out to be useful in the efficacy evaluation and the safety prediction of oncology drugs. While the diversity and the degree of engagement in genetic changes in the initiation of cancer cell growth and progression are widely accepted, it has become increasingly clear that the roles of host cells, tissue microenvironment, and the immune system also play important roles in cancer. Therefore, the methods used to develop oncology drugs should continuously be revised based on the advances in our understanding of cancer. In this review, we extensively summarize the effective use of those models, their advantages and disadvantages, ranges to be evaluated and limitations of the models currently used for the development and for the evaluation of oncology drugs.
Progress of Cancer Biology is Closely Linked to Oncology Drug Development
T he history of the development of oncology drugs, so-called chemotherapeutic agents, is closely associated with the progress of the biological understanding of cancer. Based on the concept that cancer cells are capable of unlimited proliferation, substances that inhibit DNA replication or cell division have been used as drugs for cancer treatment for a long period, since the 1950s. Although the concept has remained unchanged to the present day, (1) the discovery of cancer cell-specific metabolic pathways has led to the development of antimetabolites. (2) After the discovery of cancer cell-specific molecular and cellular mechanisms that are essential for the survival and growth of cancer cells, therapeutic drugs targeting these mechanisms, so-called molecular targeted drugs, started to be developed. (3) Research into viral oncogenesis, started in the 1960s, led to the discovery of oncogenes, (4) and research into the genetic backgrounds of cancers led to the discovery of tumor suppressor genes. (5) In the course of such studies, it also became apparent that cancer is caused by genetic abnormalities such as mutations, deletions, duplications, and translocations. (6) (7) (8) (9) Molecular targeted cancer drugs appeared in the 1990s; (10) can-cer was considered a disease characterized by abnormal differentiation, and the efficacy of differentiation-inducing agents was demonstrated. (11, 12) Furthermore, it was shown that a solid tumor tissue consists of cancer and host cells such as vascular cells, fibroblasts, and cells in the immune system and that these host cells are essential for tumor growth. Drugs targeting the function of these host cells and their interactions with cancer cells were proven to be effective. (13) Based on these findings, it has been thought that regulatory mechanisms for the entire organism are involved in the action of oncology drugs that regulate the immune system. (14) Significance of Non-Clinical Studies in Efficacy Evaluation and Safety Prediction Non-clinical studies are necessary at each stage of the development of oncology drugs. Particularly, the efficacy and the safety of a drug must be examined and evaluated before undertaking any clinical study of the drug. Types of non-clinical studies and how critical they are vary depending on the types and mechanisms of action of oncology drugs. Non-clinical studies required to develop drugs targeting cancer-host interactions differ markedly from those on substances having direct killing effects on cancer cells. Many experimental cancer models (animal models, ex vivo models, and in vitro models) have been developed to investigate carcinogenesis, cancer progression, metastasis, and other aspects in cancer biology. These models turned out to be useful in the efficacy evaluation and the safety prediction of oncology drugs. The present review summarizes the effective use of those models, their advantages and disadvantages, ranges to be evaluated, and limitations of the models used in non-clinical study.
Evaluation of Oncology Drugs Using Experimental Animal Models
Two classes of experimental animal models for human cancers are currently used for the evaluation of oncology drugs: transplantation models and autochthonous cancer models. Transplantation models have been playing an important role in the non-clinical evaluation of oncology drugs. They are generally categorized into two types, namely xenograft models using human cancer cells and orthograft models using murine cancer cells. There has been some debate that the efficacy evaluation of oncology drugs in transplantation models might not be adequate for predicting the clinical efficacy or the types of cancer for which the drug could be effective. As autochthonous cancer models, chemical carcinogeninduced models were first established and the subsequent technological progress in gene manipulation allowed researchers to produce models harboring the genetic mutations of human cancer. Although a number of technical issues regarding the ability to maximize the utility of these models need to be addressed, such as their usability, reproducibility, and throughput compared with transplantation models, autochthonous cancer models clearly show some promise. In Table 1 , we summarize the characteristics of those experimental cancer models used to evaluate the efficacy of oncology drugs in non-clinical studies.
Transplantation cancer models. In general, the s.c. (heterotopic) transplantation models with cancer cell lines have been used, and the efficacies of oncology drug response are evaluated based on tumor size. These models are particularly useful when a drug has a marked antiproliferative effect on cancer cells. It is also easy to access tumor tissue samples from these models for subsequent pharmacodynamic evaluations. Despite such clear advantages, these models may not reflect the actual characteristics of the cancer microenvironment because the s.c. tissue is "heterotopic" for most cancer cells. In this context, orthotopic transplantation models may reproduce the cancer microenvironment more faithfully, although their utility caused by species differences should be considered. To analyze metastasis dissemination of cancer cells, experimental metastasis models have been considered as useful for evaluating drug efficacy in the process after the invasion of cancer cells from the primary tumor into the nearby blood vessel. Although these models have clear advantage in their usability and reproducibility, they cannot reproduce the entire step before the extravasation of cancer cells and may not accurately represent actual metastases by injecting a substantial number of cancer cells into the blood vessel. In this regard, spontaneous metastasis models have been considered to reflect the process of the metastasis of cancer cells more accurately than the heterotopic or orthotopic transplantations. Despite the clear advantages of these models, only a limited number of cancer cell lines are available and the results of experiments often vary. In addition to the above transplantation cancer models with cancer cell lines, patient-derived xenograft models have been considered as emerging animal models recapitulating the clinical condition of individual cancer patients, and therefore attracted much attention on precision treatment. (15) (16) (17) Autochthonous cancer models. There are two major types of autochthonous cancer models, carcinogen-induced models and gene-engineered mouse (GEM) models. Of these, GEM models have been regarded as a better choice for testing drug efficacy, because the drug effects can be evaluated on autochthonous cancer cells induced by gene mutations resembling human cancer. As summarized in Table 2 , there are several pros and cons to using autochthonous cancer models for drug efficacy tests in non-clinical studies. In particular, the timing of tumor occurrence and tissue specificity are often the major concerns of carcinogen-induced models and conventional knockout ⁄ transgenic mice. To overcome these issues, conditional gene knockout or gene expression technology provide us with the opportunity to use GEM models that more closely represent the pathology of human cancers. In addition to the above technical difficulties, the administrative challenges, such as maintenance of mouse strains to acquire a sufficient number of mice as well as the characters of each mouse model, including the latency and incidence of tumor and other relevant issues, need to be considered before undertaking efficacy studies testing oncology drugs in GEM models. Nevertheless, new technologies, such as in vivo imaging methods for small animals, have been introduced as powerful tools for quantitative evaluation of cancer occurrence and subsequent growth in GEM models. In Table 3 , GEM models developing tumors induced by genetic mutations found in corresponding human cancers are summarized.
Spontaneous cancer models using companion animals. Even in companion animals, such as dogs and cats, the incidence of cancer has been increasing, likely due to their life extension together with genetic factors. In fact, cancer has become the leading cause of death among those companion animals. In particular, it has been known that the mortality from cancer is reported to be 47% (based on the report by the Veterinary Cancer Society, http://www.vetcancersociety.org/members/) in large breed dogs aged 10 years or more. Therefore, the establishment of early diagnosis methods and the development of therapeutic drugs for cancer in companion animals is being actively pursued in the USA and Europe. Considering the pathology of cancer in large breed dogs seems to be similar to those in humans, (68) the utility of spontaneous cancer in large breed dogs for testing new oncology drugs has already been initiated in the USA and Europe. (69) In Japan, the leading cause of death in dogs is also cancer with a mortality of 54% ("The Ten Leading Causes of Death in Dogs and Cats" reported by the Animal Insurance System Japan Animal Club), which is much higher than the mortality rate of other diseases such as heart disease (17%). Given these circumstances, studies for developing methods for the diagnosis and treatment of cancer in dogs have been actively initiated. Based on the results of these studies, the Japanese Society of Clinical Veterinary Medicine have been discussing the significance of cancer models using companion animals in non-clinical studies for developing oncology drugs as well as preparing for the establishment of relevant administrative and management systems for its application.
Evaluation of Oncology Drugs that Directly Target Cancer Cells
The efforts of oncology drug development originally concentrated on the production of drugs that directly target the proliferation or metabolic properties of cancer cells. Along with discovery of oncogenic driver genes, development of molecular targeted drugs has been highlighted, which directly pinpoint signal transduction pathways involving those driver genes, as well as the protein degradation systems, epigenome, and metabolic systems of cancer cells. As molecular targeted drugs, tyr-osine kinase inhibitors (TKI), multi-targeted kinase inhibitors (MTKI), and drugs that target molecular mechanisms for cell cycle regulation and others have been successfully developed. Although the classical anticancer chemotherapeutic drugs also show cytotoxicity by attacking specific intracellular molecules, the term "molecular targeted drug" in this report is defined as a drug that has been developed through primary identification of a molecule or a signaling pathway as a therapeutic target, which is highly activated or deregulated in cancer cells. Table 4 summarizes the pros and cons for evaluating molecular targeted drugs in non-clinical cancer models. The results produced by the use of these models have been included in the application of new drugs; the models believed to be essential. Tyrosine kinase inhibitors and other kinase inhibitors. Tyrosine kinase inhibitors include epidermal growth factor receptor inhibitors (gefitinib, erlotinib, lapatinib, and afatinib), human epidermal growth factor receptor 2 inhibitors (lapatinib and afatinib), anaplastic lymphoma kinase inhibitors (crizotinib, ceritinib, and alectinib), BCR-ABL inhibitors (imatinib, dasatinib, nilotinib, ponatinib, and bosutinib), a KIT inhibitor (imatinib), SRC inhibitors (dasatinib and bosutinib), a JAK inhibitor (ruxolitinib), a Bruton's tyrosine kinase inhibitor (ibrutinib), and a dual kinase MEK inhibitor (trametinib). There are several other kinase inhibitors, including BRAF inhibitors (vemurafenib and dabrafenib), a phosphatidylinositol-3 kinase inhibitor (idelalisib), and mammalian target of rapamycin inhibitors (temsirolimus and everolimus). In addition, drugs that target p38, AKT, p70S6 kinase, insulin-like growth factor 1 receptor, platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), MET, ROS 1, and RET are currently being developed. For evaluating the effica- This table summarizes the advantages and potential problems in various types of genetically engineered mouse models for use in preclinical studies of oncology drugs. NA, not applicable. 
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Msh3/Msh6
Conventional KO Lymphoma, (52) tumor of the digestive tract, (54) skin tumor (53) 
. Similarly to TKIs, the efficacy of MTKIs can be evaluated in non-clinical cancer models. However, MTKIs target multiple kinases and it is generally difficult to prepare genetically engineered cell lines that reproduce the pathology of the target cancers. In the case of MTKIs that target angiogenic factors, such as VEGFR, FGFR, and PDGFR, accurate prediction of in vitro efficacy would be difficult: pazopanib, for example, does not necessarily show a direct antiproliferative effect on many cancer cell lines in vitro, but it significantly inhibits tumor growth in vivo by blocking angiogenesis. (74) Also, because MTKIs could have multiple modes of action, establishment of the proof-of-concept at the pharmacodynamic level in non-clinical cancer models might require a complex procedure.
Targeting cell cycle. Palbociclib inhibits cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), which are involved in cell cycle control. Furthermore, drugs targeting various cell cycle regulators, such as WEE1, cell division cycle 7, checkpoint kinase 1 and 2, ATR, Aurora, PLK, and mitotic kinesins, are under clinical development. Efficacies of these drugs can be evaluated using relevant cancer cell lines that have abnormalities in the target molecules or their regulators (e.g. CCND1 ⁄ CDK6 amplification or CDKN2 deletion ⁄ mutation) in transplantation models.
Targeting protein degradation systems. Protein degradation systems have been recognized as an emerging therapeutic target for particular types of cancer. While several target molecules have been described in this category, proteasome inhibitors, such as bortezomib and carfilzomib, have been developed most extensively and approved as anticancer drugs. Meanwhile, other molecular targets include the NEDD8-activating enzyme, the ubiquitin-activating enzyme, and stress proteins that are involved in protein folding, such as heat shock protein 90 and glucose-regulated protein 78. Given that the preferential efficacies of proteasome inhibitors against multiple myeloma have been well established, transplantation models with multiple myeloma cell lines could be applicable for evaluating the efficacy of the drugs in this category. However, there are several potential issues and limitations for predicting the clinical efficacy of these drugs from non-clinical cancer models: detailed mechanisms for the action of the drugs and predictive biomarkers for the drug responses are rather elusive, and cancer types that are susceptible to the anticancer effects of the drugs in non-clinical studies may not be consistent with those in the clinical settings. Therefore, the latest knowledge from basic research and clinical phase I studies on various cancer types should be taken into consideration for additional indication of the drugs.
Targeting genomes and epigenomes. The anticancer efficacies of drugs that target cancer epigenomes, such as DNA methyltransferase inhibitors (azacytidine and decitabine) and histone deacetylase (HDAC) inhibitors (vorinostat, panobinostat, romidepsin, and belinostat), have been shown in vivo, although the cancer types against which the drugs are effective differ between the non-clinical studies and clinical practice in some cases. (84) As these drugs affect many target sites in a genomewide manner, detailed mechanisms and predictive biomarkers for the drug response often remain elusive. Drugs targeting the genomic repair systems include poly(ADP-ribose) polymerase (PARP) inhibitors, such as olaparib. Because there is a synthetic lethal relationship between PARP and tumor suppressors, BRCA1 and 2, It would be relatively easy to predict the therapeutic efficacy of PARP inhibitors by using transplant models of cell lines with BRCA1 or 2 deficiency. (85, 86) Besides BRCA1 ⁄ 2, it has been also postulated that there are many synthetic lethal factors with PARP inhibition. However, the clinical validity of those candidates has not been fully established. However, it should be also noted that synthetic lethality confirmed in the non-clinical studies (e.g. effect of a PARP inhibitor on EWS-FLI1-positive Ewing's sarcoma) (87, 89) could be sometimes abolished by the formerly applied therapies in the clinical settings.
Targeting cancer cell metabolisms. Metabolic enzymes favored by cancer cells, such as isocitrate dehydrogenases 1 ⁄ 2 (IDH1 ⁄ 2) and fatty acid synthase, are potential targets for cancer therapy. For IDH1 ⁄ 2 inhibitors, transplant models of IDH1 Conditional KO R26-CreERT2 Basal cell tumor (20) Mouse models reproducing generative tissues and mutations found in human caner. While many other scientifically excellent mouse models for human cancers have been generated, the table preferentially lists those harboring relatively simple mutant alleles suitable for preclinical studies. It should be noted some mouse models do not completely recapitulate pathologies of human cancer. (70) Alternative cell lines into which target (mutant) genes are transfected (71) (e.g.
Ba ⁄ F3) (ii) GEM models (29) Can predict ⁄ evaluate drug efficacy in the model with potent driver gene activities and oncogene addiction (72) Can generate resistant cells as negative control
Can establish proof-of-concept pharmacodynamically by evaluating autophosphorylation of target kinases or phosphorylation of downstream factors (i) Cancer cell lines may change their phenotypes during the process of their establishment due to selective pressure and stresses (ii) Alternative cell lines may not accurately replicate the etiology of the relevant cancer types Kinases (multitargeted) RAF, VEGFR-2, PDGFR-b, KIT, FLT-3, RET, EGFR, MET, RET, TIE-2, TRKB, AXL, SRC, LCK, LYN The same as (i) and (ii) above (31) For anti-angiogenic agents, Matrigel plug assay could be used (73) Can predict ⁄ evaluate drug efficacy in the model with potent driver gene activities (31) In addition to (i) and (ii) above: It is difficult to generate alternative cell lines reproducing the pathology of target cancers by genetic engineering when the drug acts on multiple kinases in the target cancer cells
In vitro cell growth assays do not reflect the antiangiogenic action in vivo (74) May require complicated pharmacodynamic analyses due to the presence of multiple targets MAPK pathway
MEK, BRAF, p38
Cancer cell lines with mutations in the target pathway of interest (target molecule or upstream target) or transplantation animal models with alternative cell lines generated by genetic engineering (75, 76) GEM models (27) Can predict ⁄ evaluate drug efficacy in the model with potent driver gene activities (77) Can establish proof-of-concept pharmacodynamically by evaluating phosphorylation of downstream factors In addition to (i) and (ii) above:
(iii) It is difficult to achieve sufficient drug response in some cancer types including colorectal cancer with less potent driver activities, in which other coexisting (i.e. not mutually exclusive) driver pathways contribute to tumor proliferation (77) PI3K ⁄ mTOR pathway PI3K, mTOR, AKT, p70S6K Cancer cell lines with mutations in the target pathway of interest (target molecule or upstream target) or transplantation animal models with alternative cell lines generated by genetic engineering (78) GEM models (33) Can predict ⁄ evaluate drug efficacy in the model with potent driver gene activities (79) Can establish proof-of-concept pharmacodynamically by evaluating phosphorylation of downstream factors The same as (i), (ii), and (iii) above Cell cycle CDK4 ⁄ 6, WEE1, CDC7, CHK1, CHK2, ATR, Aurora, PLK, mitotic kinesins Cancer cell lines with mutations in the target pathway of interest (target molecule or upstream target) or transplantation animal models with alternative cell lines generated by genetic engineering (80) Drug efficacy may be achieved in cancer cell lines with an abnormality as shown in the left-hand column
The same as (i), (ii), and (iii) above (R172) mutant-positive AML or glioma cell lines (88) Can predict ⁄ evaluate drug efficacy by examining the presence of mutation Pharmacodynamic study can be carried out by monitoring mutation-specific metabolites (oncometabolites) (88) Drugs targeting molecules that produce no oncometabolites may be effective to a wider range of cancer types If the target produces no oncometabolites, mechanisms of action or predictive biomarkers for the drug response may not be available and it may be difficult to design evidence-based studies to evaluate the drug response This table classifies the target molecules of approved ⁄ investigational drugs used in Japan, overseas, or both and lists representative non-clinical evaluation methods of these drugs. Due to their usefulness and usability, evaluation results have been used for publication data of original papers and oncology drug application dossiers for approval. Meanwhile, it should be noted that these technologies have technical limitations and contain a number of limitations ⁄ problems attributable to the properties or unclarified factors of target molecules and diseases. ALK, anaplastic lymphoma kinase; BTK, Bruton's tyrosine kinase; CDC7, cell division cycle 7; CHK, checkpoint kinase; DMNT, DNA methyltransferase; EGFR, epidermal growth factor receptor; FGFR, fibroblast growth factor receptor; GRP, glucose-regulated protein; HDAC, histone deacetylase; HER2, human epidermal growth factor receptor 2; HSP, heat shock protein; IDH, isocitrate dehydrogenase; IGF1R, insulin-like growth factor 1 receptor; MDS, myelodysplastic syndromes; mTOR, mammalian target of rapamycin; PARP, poly(ADP-ribose) polymerase; PDGFR, platelet-derived growth factor receptor; PI3K, phosphatidylinositol-3 kinase; VEGFR, vascular endothelial growth factor receptor.
(R132) or IDH2(R172) mutation-positive AML and glioma cell lines are useful for predicting drug efficacies. (88) The pharmacodynamics of these drugs can be evaluated by monitoring the mutation-specific metabolite (oncometabolite), 2-hydroxyglutaric acid. However, if the target molecule does not produce a characteristic oncometabolite, one may expect a broader spectrum of anticancer efficacies of the inhibitors. In that case, however, it may be relatively difficult to evaluate Animal (mainly mouse) models used for the evaluation of oncology drugs targeting angiogenesis and tumor stroma are classified in this table.
As the efficacy of these drugs depends on cancer-host interactions or host factors, consideration should be given to the cross-reactivity of therapeutic drugs and ⁄ or their target molecules between species (mainly between humans and mice). CAM, chick chorioallantoic membrane; GEM, gene-engineered mouse; mTOR, mammalian target of rapamycin; PDX, patient-derived xenograft; TKI, tyrosine kinase inhibitor; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor.
the efficacy of the drugs because the mechanism of action and predictive biomarkers would remain unclear.
Targeting Cancer Cell-Host Interactions
The importance of microenvironments on the growth, progression, and therapeutic resistance of cancer cells has been drawn much attention. Such tumor microenvironments have been known to support cancer cell proliferation directly or indirectly through interactions between surrounding stroma cells. In general, it is relatively difficult to carry out an appropriate in vivo efficacy test for drugs targeting interactions between cancer cell and host microenvironment in non-clinical cancer models. Targeting angiogenesis. It has been widely recognized that generation of new blood vessels into tumor (angiogenesis) is a critical step for cancer cells to be adequately supplied nutrition and oxygen, therefore, it is assumed that tumors are unable to grow progressively without angiogenesis. There are also several relevant studies suggesting that angiogenesis is involved in not only cancer cell proliferation but also cancer cell progression, including metastases to distant organs. As represented by VEGF inhibitors (bevacizumab), drugs targeting angiogenesis may not exert direct antitumor effects on cancer cells, however, should inhibit the activity of various angiogenic factors that mainly affect vascular endothelial cells for generating new blood vessels. Consequently, non-clinical evaluation of the efficacy of drugs targeting angiogenesis can be greatly affected by host factors in experimental animals; therefore, it is critical to use appropriate models for drug evaluation, as summarized in Table 5 .
For carrying out appropriate in vivo tests for drugs targeting angiogenesis, it is very important to consider whether cancer cell lines or patient-derived samples produce angiogenic factors for targeting and, moreover, their cross-reactivity in non-clinical cancer models. It is also relevant for other angiogenesis models such as the Matrigel plug assay, chick chorioallantoic membrane assay, or hollow fiber assay.
Targeting cancer stroma. Diverse cellular components of tumor stroma (e.g. fibroblasts, mesenchymal cells, and inflammatory cells) and extracellular matrices (e.g. fibronectin, collagen, laminin, and proteoglycan) have been shown to be involved in cancer cell proliferation and progression. Although tumor stroma is expected to be an attractive therapeutic target, the development of drugs targeting cancer stroma is still in the early stages.
Similar to those targeting angiogenesis, non-clinical evaluation of drugs targeting tumor stroma should be greatly affected by host factors. In immune-compromised mice (e.g. nude, SCID, NOD ⁄ SCID, and NOG) often used for transplantation models of human cancer cells display a range of different Table 6 . Evaluations of drugs targeting host immune response
Model
Outline Characteristics Problems
Allograft model Syngeneic (mainly mouse) cancer cell lines implanted into s.c. as heterotopic transplantation models, or implanted into original tissues ⁄ organs in orthotopic transplantation models, or injected into tail vein as metastasis models Use of cell lines with ectopic expression of model antigens (e.g. OVA, (90, 91) HA, (92) CEA (93) ) or cell lines known with their immunogenicity (e.g. B16 melanoma, (94) Meth A, (95) colon 26 (96) )
Immune responses against cancer cells can be monitored over time and the mechanism of action can be tested Tumor antigen-specific immune responses can be evaluated where antigens have been specified Orthotopic transplantation models and metastasis models may be better for analyzing tumor-infiltrating lymphocytes considering the organ microenvironment of cancer cells. Antitumor activities can be analyzed by using human (cancer patients') immune cells.
Limitation for analyzing immune responses due to its incompetence of the intact immune system Application of humanized mice engrafted with human immune cells clearly requires further investigation Animal (mainly mouse) models used for evaluating drugs targeting host immune response are classified in this table. As the efficacy of cancer immunotherapy depends on the host's immune system, concurrent use of multiple models should also be considered. In such a case, it is necessary to devise optimal combinations of models to be used, taking into account the potential limitations ⁄ problems of each model presented in the immunological environments. Even in these immune-compromised animals, myeloid compartment and mesenchymal cells are known as relatively normal, therefore the efficacy of drugs targeting those stromal cells may be evaluated even in animal models if the target shows cross-reactivity between species.
Targeting host immune responses. The immune system has been regarded as an important constituent of the tumor microenvironment. Many series of studies have been undertaken to understand the regulatory mechanisms by which cancer cells control, either positively or negatively, hosts' immune responses. Recent clinical successes of immune checkpoint inhibitors, such as anti-CTLA-4 mAbs (ipilimumab and tremelimumab) and anti-PD-1 mAbs (nivolumab and pembrolizumab) highlight targeting hosts' immune responses against cancer cells as a promising target for drug development.
Obviously, drugs targeting hosts' immune responses should be tested in the appropriate non-clinical cancer models in which the targets are involved in the immune responses against cancer cells, for elucidating the mechanisms of action and predicting potential side-effects. In general, it is ideal to test the importance of drug targets or potential drug candidates in different experimental models (multiple cell lines, different mouse strains). Considering there should be a limitation for predicting cancer types to which the drug shows clinical benefit by testing only in non-clinical models, the results of phase I clinical studies need to be carefully considered. For testing drug candidates in which certain HLA haplotypes are required to show antitumor effects (e.g. cancer vaccine therapy), an application of humanized mice may be worth considering as non-clinical models. In Table 6 , we summarize pros and cons of non-clinical models for testing drugs targeting hosts' immune responses.
Evaluation of Oncology Drugs Based on New Concepts
Along with gaining our knowledge with the biological characteristics of cancer, there are several new approaches to develop oncology drugs, such as targeting cancer stem cells.
Targeting cancer stem cells. The concept of cancer stem cells was originally introduced in hematological malignancies and further extended to solid cancers such as breast cancer and brain tumors. (97) Cancer stem cells have been characterized by their self-renewal potential, multidirectional differentiation potential, and niche dependence, similar to other stem cells, in addition to their highly tumorigenic potential. Furthermore, cancer stem cells have been known for their resistance to conventional chemotherapy or radiotherapy; therefore, they may be an emerging target for drug development. In Table 7 , we summarize the current methods for testing drugs targeting cancer stem cells in non-clinical evaluations.
Targeting other novel concepts or methods. In Table 8 , we summarize the current status of oncology drug development targeting new concepts other than cancer stem cells, or novel methods for developing new oncology drugs. Non-clinical evaluation of some of those oncology drugs targeting novel concepts may require approaches that are different from those used for the evaluation of conventional oncology drugs. A deeper understanding of the biological characteristics of cancer is leading to the development of novel oncology drugs based on new concepts such as "cancer stem cells" in addition to the developmental targets presented in earlier sections.
Concluding Remarks
This review summarizes present non-clinical investigations by listing the common methods currently used for the development of oncology drugs as extensively as possible. Their types, profiles, and problems are briefly described. Characteristics of a variety of animal models, which provide indispensable information to formulate clinical research and clinical trials, are summarized according to each category of oncology drug. Experimental models obtain the proof of evidence at the molecular, cellular, and tissue levels, and unique oncology drugs are also covered. It is hoped that this review provides information to undertake regulatory science relevant to the development of oncology drugs.
Studies with cancer models, including animal experiments, ex vivo studies, and in vitro studies, are essential technology in cancer biology and have contributed to the development and evaluation of oncology drugs. Particularly, cancer cell lines derived from humans and experimental animals have been used for decades as indispensable tools for the biological understanding of cancer and for the development of oncology drugs. Properties of cancer cells represented by a cell have been changing cell line, it was discovered that the accumulation of multiple abnormalities in genes causes cancer and that the properties of individual cancer cell lines depend not only on their organ origins but also on the types of abnormal genes. Growing knowledge on cancer as a disease has led to the understanding that interactions between cancer and host cells and the regulatory molecules play critical roles. The growth of tumors strongly depends on tissue microenvironments and immunological milieu that are difficult to reproduce in vitro. As shown in this review, a substantial number of models reflecting these various aspects of cancer-host interactions have been developed in the past decade. These models have significantly contributed to the expansion of the range of nonclinical studies and their role, in the exploration, development, and clinical investigation of oncology drugs have become indispensable.
The diversity and the degree of engagement in genetic changes in the initiation of cancer cell growth and progression are widely accepted. The roles of host cells, tissue, and the immune system also vary depending on the type, properties, and the stage of individual tumors are also becoming clear than before. Therefore, the methods used to select and use oncology drugs should continuously be revised based on the This table exclusively presents oncology drugs that are being or about to be investigated in Japan and overseas based on new concepts. †Although "Cancer cell line panel" cannot be classified as a therapeutic drug, it is presented here as an assay that is extensively used in the development of new therapeutic drugs. DDS, drug delivery system; iPS, induced pluripotent stem cells. advance in understanding of cancer. As stated earlier in this review, models established for the biological understanding of cancer have proven to be useful as tools for non-clinical investigations. When developing a new drug that is in the same class as those for which efficacy and safety information was already acquired from clinical studies, it is also useful to select non-clinical models based on the clinical information. Collectively, it will become increasingly important to design, to select, and to use appropriate non-clinical models in order to design clinical research and trials. Investigations with these models should be effective in interpreting the results of such investigations and to re-evaluate the effects of oncology drugs used in clinical practice. It is strongly hoped that non-clinical investigation will continuously be successfully used for the development, approval, and proper use of oncology drugs, which accelerate drug development.
